Original research
par
Run Min, Jeong, et al
Date de publication
2024
Géographie
Canada
Langue de la ressource
English
Texte disponible en version intégrale
Oui
Open Access / OK to Reproduce
Oui
Évalué par des pairs
Yes
L’objectif
Is coprescription of hydromorphone tablets or sustained-release oral morphine (opioid risk mitigation guidance [RMG]) and opioid agonist treatment (OAT) associated with subsequent OAT receipt?
Constatations/points à retenir
This study, which acknowledged the intermittent use of both medications, demonstrated that individuals who were coprescribed opioid RMG had higher adjusted probability of continued OAT receipt or reengagement compared with those not receiving opioid RMG.
La conception ou méthodologie de recherche
This population-based, retrospective cohort study was conducted from March 27, 2020, to August 31, 2021, included individuals from 10 linked health administrative databases from British Columbia, Canada.
Mots clés
About PWUD
Clinical guidance
Evidence base
Safer supply
Substitution/OAT
Transitions in care/treatment
